Clair Health is building a wrist-worn hormone tracker for women. The startup has raised $11.6 million in fresh funding to bring the device to market. Khosla Ventures led the round. Clair is tackling a problem that remains surprisingly outdated. Many women still rely on blood tests, urine strips, cycle-tracking apps, and general fitness wearables to understand their hormonal health. Founded in 2025 by Stanford graduates Jenny Duan and Abhinav Agarwal, the company offers a different approach. Its platform combines a wearable bracelet and mobile app to provide continuous hormone insights instead of one-time snapshots.
That’s a bold promise.
It gets more complicated once real hardware, real biology, and real regulatory limits show up.
What is the Clair Health wearable and how does it work?
The Clair Health wearable is a bracelet-style device paired with a mobile app. It continuously tracks hormone-related patterns using physiological signals. This reduces the need for calendar-based predictions and one-time hormone tests. The system uses 10 biosensors, including a biomagnetic sensor. Its AI models analyze more than 130 biomarkers to estimate cycle phases and track how hormonal changes may affect energy levels, sleep, recovery, and symptoms. The company is building toward tracking estrogen, progesterone, LH, FSH, and PdG in real time.
For users, the flow sounds pretty simple. There’s voice-based onboarding to capture symptoms and health context in a more open-ended way than a checkbox-heavy period app. The app then turns sensor data into outputs like period and fertile-window predictions, hormone charts, performance guidance, personalized insights, and partner-sharing features. Duan’s argument is that most women’s health apps force people into narrow inputs, while Clair’s voice layer lets them describe “their own problems in their own way.”
The bigger product idea is consolidation. Many women currently juggle 3 separate workflows — a cycle app, at-home hormone tests, and a wearable like Oura or Whoop. Clair wants to collapse that into one device and one app. It treats cycle phase as a core signal rather than background noise. The company also says all AI processing happens on the phone, not in a remote data center, and that cloud backup is optional and encrypted.
There’s some early validation behind the pitch, though it’s still early. Clair tested its prototype on 40+ women across 127 menstrual cycles and reached 94.1% accuracy for cycle-phase classification from wearable data alone, with 87% sensitivity for LH surge detection and about 84.3% accuracy on irregular cycles. The current product is framed as a general wellness device, while a later Clair 2.0 is supposed to pursue FDA 510(k) clearance for more medical-grade claims.
Who founded Clair Health and what has it built so far?
The founding story
Clair started after Duan and Agarwal met at Stanford in spring 2025 and began working on the idea soon after. Duan’s interest in women’s health predates the startup: she has said the spark came from working with women experiencing homelessness and domestic violence through Rose Haven in Oregon, where she saw how often women’s symptoms were dismissed when they couldn’t produce hard data. A Stanford course on women’s health and nonprofits helped push that interest from frustration into startup mode.
That founding logic still runs through the company’s messaging. Clair isn’t just selling convenience. It’s selling evidence — the idea that better longitudinal data could help women show up to medical appointments with more than memory and guesswork.
Why these founders make sense for this product
Duan graduated from Stanford with a B.S. in Symbolic Systems, and her background mixes women’s health advocacy, startup work, growth marketing, and venture exposure. She has also tied her early product instincts to work at Daydream and investing experience through Anthos, which helps explain why Clair is being framed as both a health device and a consumer brand.
Agarwal brings the sensor and wearable angle. Stanford coverage lists him as a Stanford graduate with a B.S. ’24 and M.S. ’25, and Clair’s materials associate him with the Stanford wearables world. The split is pretty clean: Duan is the market-maker and storyteller. Agarwal is the builder on the device side. For a startup trying to make hardware feel good, look good, and say something medically useful, that combo matters.
Early traction, preorders, and the round itself
Clair is still pre-launch, but it’s past the idea-stage hand waving. The startup has been testing the product with a closed beta group, and preorders are open. The source report said the device was slated to ship in November at $369 with a $9.99 monthly subscription. Clair’s current preorder page uses a more specific date — Founding Members ship in December 2026 — and lists a 20% early price cut to $295, with 6 months of Clair Pro included. The first 5,000 Founding Member slots have already sold out.
On funding, there’s a small reporting discrepancy worth being straight about. The source article puts the round at $11.6 million and lists Khosla Ventures as lead, with participation from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, Anne Wojcicki, and Stephanie Coleman. A newer Fortune report from June 17, 2026 describes it as an $11 million seed round led by Khosla with many of the same backers.
How does Clair compare with rivals and incumbents?
The direct competition comes from a few different directions. There are general-purpose wearables like Apple Watch, Pixel Watch, Oura, and Whoop, which already capture temperature, heart rate, and HRV but weren’t built around hormone inference. Then there are hormone-specific approaches like Level Zero Health, which is pursuing continuous monitoring with a patch-style path closer to glucose monitoring, and Hormona, which leans on at-home testing. On the software side, apps like Ourself still depend heavily on user logging and interpretation.
Clair’s differentiation pitch is pretty clear. It wants noninvasive tracking and women-specific modeling. It also wants a wrist form factor that looks like a wearable people might actually keep on, plus privacy that stays on-device. It’s also going after more than fertility. The company talks about inflammation, bloating, perceived exertion, cycle irregularities, perimenopause, and eventually conditions like endometriosis and PMDD.
That broader framing makes sense. It also raises the bar on proof. A startup can’t just say “hormones” and expect people to believe it anymore.
Why does the Clair Health wearable funding round matter?
Because this round moves Clair out of concept territory.
There are tons of health startups that sound smart in a demo and then hit the wall when they have to manufacture hardware, support users, handle privacy, run clinical work, and keep the whole thing wearable enough that people don’t abandon it after 2 weeks. A seed round of this size gives Clair a shot at covering all of those jobs at once.
It also backs a specific investor thesis. Khosla and the other investors aren’t just betting on cycle tracking. They’re betting that women’s health can support a more defensible product stack — hardware, models, app subscription, and eventually regulated claims. Mary Minno of Treehub made the appeal pretty blunt: hormonal measurement is still “archaic,” and many perimenopausal women still rely on blood draws to understand whether treatments are working.
There’s a second layer here. Clair says it has data partnerships that give it access to several million electronic health records and longitudinal datasets, with plans to build insights around endometriosis, PMDD, and perimenopause. If that work turns into something clinically credible, the company could become more than a fancy cycle tracker. If it doesn’t, it risks becoming another attractive wearable with ambitious copy and limited medical usefulness.
How big is the market for hormone-tracking wearables?
Big enough that investors keep showing up.
Grand View Research estimates the global women’s health app market at $4.85 billion in 2024, with a forecast to reach $12.87 billion by 2030, growing at a 17.8% CAGR from 2025 to 2030. That doesn’t map perfectly to hormone-tracking wearables, but it does show where consumer demand is heading. More specialized women’s health products and recurring software layers. More interest in health tools that go beyond pregnancy and period reminders.
The timing also makes sense for non-market-size reasons. Women are asking for more passive tracking and less manual logging. Perimenopause is finally getting more product attention. Privacy worries around reproductive data are now a real buying factor, not a niche talking point. Sensor-driven health products are maturing fast enough that startups can credibly argue the body has been broadcasting these signals all along — we just didn’t have the models to read them. Clair is arriving right in the middle of that shift.
Final take on the Clair Health wearable
The Clair Health wearable is one of the more ambitious femtech hardware bets in a while, mostly because it’s trying to do something harder than prettier period tracking. It wants to turn passive wearable signals into hormone-aware insight that feels useful in everyday life and credible in clinical conversations.
But ambition isn’t the same thing as proof.
What to watch next is simple: whether Clair ships on time in late 2026, whether independent validation holds up outside company-run testing, and whether this continuous hormone monitor can earn trust as something more than a very polished promise.
Read how Critical Energy raised a $19M seed round led by Susa Ventures and Upfront Ventures to build modular geothermal turbines that help developers deploy always-on clean energy faster through factory-built power generation systems.
FAQ
- What funding did Clair Health raise?
Clair Health raised $11.6 million in a round led by Khosla Ventures, with backing from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, Anne Wojcicki, and Stephanie Coleman. A Fortune report published on June 17, 2026 described the financing as an $11 million seed round, so there’s a small difference in how the raise has been reported. - How does the Clair Health wearable work?
Clair’s device is a wrist-worn wearable tied to a mobile app that uses a 10-sensor stack and AI models to infer hormone-related patterns from continuous physiological data. The company says it tracks signals tied to estrogen, progesterone, LH, FSH, and PdG, then turns those into cycle-phase insights, predictions, charts, and wellness guidance without relying on blood draws or urine strips. - Who founded Clair Health?
Clair Health was founded by Stanford graduates Jenny Duan and Abhinav Agarwal after the two met in 2025 and started building soon after. Duan studied Symbolic Systems and came to the idea through women’s health advocacy and startup work, while Agarwal brought the wearable and sensor background. - Is Clair Health a femtech company or a wearable startup?
It’s both. Clair sits in femtech because it’s focused on women’s hormonal health, fertility timing, perimenopause, and cycle-related insights, but it’s also a wearable health hardware company because the core product is a sensor-driven device with an app and recurring subscription layer.
Leave a Reply